CSPC Megalith opens Phase 2 test of therapeutic HPV vaccine for cervical lesions
SYS6026 aims to clear HPV16/18 infection and reverse high-grade cervical lesions without surgery, in a trial that will read out by September 2028.
Executive Summary
- CSPC Megalith has registered a Phase 2 study testing whether a therapeutic vaccine can reverse high-grade cervical lesions and clear the HPV infection driving them, an approach aimed at avoiding surgical treatment.
- The trial sets a dual primary endpoint that requires both pathological regression and viral clearance together, a higher bar than trials that measure either outcome alone.
- Few programs combine this modality and this indication, and overall activity around the target has declined in recent years, making this an isolated rather than a crowded test of the approach.
- The study has not started enrolling and its earliest readout sits more than two years out, so the near-term catalyst value is limited to what the design itself signals about the sponsor's strategy.
The trial
The study, registered as NCT07702656, plans to enroll 175 participants with biopsy-confirmed cervical high-grade squamous intraepithelial lesions (HSIL, graded CIN2 to CIN3) tied to HPV16 or HPV18 infection. It is listed as Not yet recruiting, with a start date of July 10, 2026, and a primary completion date of September 30, 2028. The trial runs in China only and is not designated registrational. NCT07702656A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial LesionsNCT07702656
The endpoint bar
The primary endpoint measures the proportion of participants whose lesions resolve to CIN1 or lower and whose HPV16/18 infection clears by 36 weeks after vaccination, assessed by independent pathology review. That pairs two outcomes, histologic regression and viral clearance, into one bar rather than crediting either alone. Secondary measures track lesion downgrading and normalization at the same 36-week point, along with anti-HPV16/18 E6/E7 antibody titers, serum cytokine levels including IL-1beta, IL-6, TNFalpha and IFNgamma, and the incidence and severity of adverse events over the study period. NCT07702656A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial LesionsNCT07702656
The competitive field
No trial in the tracked landscape shares both the therapeutic-vaccine modality and the high-grade cervical lesion indication with SYS6026. The nearest peers work the same HPV16 target from different angles: NWRD08, a therapeutic vaccine from Newish Biotech tested directly in HPV16/18-related cervical HSIL, and RG002 from RinuaGene, tested in cervical intraepithelial neoplasia more broadly. Other HPV16-targeted programs pursue T-cell or TCR-T approaches in head and neck or cervical cancer rather than in the pre-cancer lesion setting, a different point in the disease course. Broader activity around the HPV16 target has declined, with 65 recent trials against 104 older ones, a ratio of 0.38.
Sponsor context
CSPC Megalith Biopharmaceutical carries 26 tracked trials across its pipeline, with 18 not yet recruiting, seven recruiting, and one active and not recruiting. SYS6026 is the company's only trial in this indication and carries no prior terminations on record. The protocol shows a single registry entry to date and no amendment history, consistent with a trial that has just been added to the registry.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.